Although the first patents for Evista (raloxifene hydrochloride) have expired, no generic versions are available at this time. However, the drug's next patent is set to expire in March 2014. It's possible that a generic version could be introduced after this date, barring any lawsuits or other patents for specific uses of the drug.
- Lowering the risk of breast cancer in postmenopausal women with osteoporosis
- Lowering the risk of breast cancer in postmenopausal women who are at high risk for it
- Treating or preventing osteoporosis in postmenopausal women.
Evista is made by Eli Lilly and Company. The drug is currently under the protection of a patent that prevents any generic versions from being manufactured in the United States. Yet, if you search the Internet for "generic Evista," you may find a number of companies selling it. The fact is that these medicines may be fake, substandard, and potentially dangerous. Generic Evista may be available from another country, but there is really no way of knowing if you are getting genuine Evista or not. You should not buy any generic versions until the Food and Drug Administration (FDA) approves one.
The first patents for Evista expired in July 2012. However, generic versions are not yet available. This strongly suggests that other patents or exclusivity rights are still providing significant protection against generic competition. The next patents set to expire will do so in March 2014. This is the earliest possible date that a generic version of the drug could become available.
However, other circumstances could come up to extend the exclusivity period beyond 2014. This could include such things as other patents for specific Evista uses or lawsuits. Once the patent expires, several companies will likely begin manufacturing generic Evista.